Skip to main content
. Author manuscript; available in PMC: 2023 Dec 21.
Published in final edited form as: ACS Chem Neurosci. 2022 Dec 6;13(24):3629–3640. doi: 10.1021/acschemneuro.2c00574

Figure 1.

Figure 1.

(a, b) In vitro pharmacology of FPT at human 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT1FRs. Note that FPT was a full agonist at 5-HT1B and 5-HT1DRs and a high-efficacy, partial agonist at 5-HT1ARs, as determined by efficacies to decrease cAMP levels relative to 5-CT. FPT’s rank order of potency, including its binding affinities as determined in competition binding assays with [3H]5-CT and its EC50 values in cAMP assays, was 5-HT1D > 5-HT1B > 5-HT1A. FPT showed nil affinity at 5-HT1FRs, so we did not test its functional activity at them. The table at the bottom of the figure summarizes the pharmacological observations. TSP, total specific binding/no compound present.